CD99: A potential Diagnostic Marker for Differentiating Sub-ependymal Giant Cell Astrocytoma From Other Mimickers: A Report of Five Cases

Document Type: Case Reports

Authors

Dept of Pathology, Iran university of medical sciences, Tehran, Iran

Abstract

Background: Tuberous sclerosis (TSC) is inherited as an autosomal dominant disease, characterized by skin lesion and tubers in vital organs, especially brain in three categories including subependymal nodules, cortical tubers and subependymal giant cell astrocytoma. Subependymal giant cell astrocytoma (SEGA) is an indolent neoplasm which usually arises at the cauda thalamic groove near foramen monro, although it occurs usually in the clinical settings of TSC,  a few number of SEGA has been reported without such history. Its morphology with special cytoarchitecture could be mistaken with other glial brain tumors with similar morphology. Therefore, investigating new markers for differentiating SEGA from other mimickers seems logical rather than other glioneural immunohistochemical markers introduced before.
Case: We investigated CD99 expression in SEGA as an adjunctive marker for diagnostic purposes. Five reported cases of SEGA were studied and all of them showed CD99 expression besides usual glioneural markers.
Conclusion: CD99 may be a useful adjunctive marker in differentiating SEGA from other mimickers

Keywords


1-O'Callaghan FJ, Lux A, Osborne J.Early diagnosis of subependymal giant cell astrocytoma in children with tuberous sclerosis. J Neurol Neurosurg Psychiatry. 2000 Jan; 68(1):118

.2-Roth J1, Roach ES, Bartels U, Jóźwiak S, Koenig MK, Weiner HLet al.Subependymal giant cell astrocytoma: diagnosis, screening, and treatment. Recommendations from the InternationaTuberous Sclerosis Complex Consensus Conference 2012.Pediatr Neurol. 2013 Dec; 49(6):439-44.

4-Jung TY1, Kim YH1, Jung S1, Baek HJ2, Lee KH3.The clinical characteristics of subependymal giant cell astrocytoma: five cases.Brain Tumor Res Treat. 2015 Apr; 3(1):44-7

5-Lopes MB1, Altermatt HJ, Scheithauer BW, Shepherd CW, VandenBergSR.Immunohistochemical characterization of subependymal giant cell astrocytomas.ActaNeuropathol. 1996; 91(4):368-75

6-JozwiaHYPERLINK "JozwiakJozwiakJ"k J1, JozwiakHYPERLINK JozwiakJozwiaSkopinski .Immunohistochemical and microscopic studies on giant cells in tuberous sclerosis.Histol Histopathol2005 Oct; 20(4):1321-6.

7-Ishizawa K1, Komori T, Shimada S, Hirose T.Olig2 and CD99 are useful negative markers for the diagnosis of brain tumors.ClinNeuropathol. 2008 May-Jun; 27(3):118-28.

8-Cenacchi G, GiangasperoF.Emerging tumor entities and variants of CNS neoplasms.JNeuropatholExp Neurol. 2004 Mar; 63(3):185-92.

9-Sterman H1, Furlan AB, Matushita H, Teixeira MJ.Subependymal giant cell astrocytoma associated with tuberous sclerosis presenting with intratumoral bleeding. Case report and review of literature.ChildsNerv Syst. 2013 Feb; 29(2):335-9.

11-Grajkowska W, Kotulska K, Jurkiewicz E, Roszkowski M, Daszkiewicz P, Jóźwiak S, Matyja E. Subependymal giant cell astrocytomas with atypical histological features mimicking malignant gliomas. Folia Neuropathol. 2011;49(1):39-46

12-Mahfouz S1, Aziz AA, Gabal SM, el-Sheikh S.Immunohistochemical study of CD99 and EMA expression in ependymomas.Medscape J Med. 2008 Feb 19;10(2):41

13-Ouyang T, Zhang N, Benjamin T, Wang L, Jiao J, Zhao Y, et al.Subependymal giant cell astrocytoma: current concepts, management, and future directions.ChildsNerv Syst. 2014 Apr; 30(4):561-70

14-Siedlecka M, Szlufik S, Grajkowska W, Roszkowski M, Jóźwiak J1.Erk activation as a possible mechanism of transformation of subependymal nodule into subependymal giant cell astrocytoma.FoliaNeuropathol. 2015; 53(1):8-14.

15-Svajdler M Jr1, Deák L, Rychlý B, Talarčík P, FröhlichováL.Subependymal giant cell astrocytoma with atypical clinical and pathological features: a diagnostic pitfall.CeskPatol. 2013 Apr; 49(2):76-9.